Minster Pharmaceuticals
Our Therapeutic Focus
Migraines
For some they are frustrating and infrequent, but for others they are a daily experience with a major negative impact on the quality of life.......
For some they are frustrating and infrequent, but for others they are a daily experience with a major negative impact on the quality of life.......
.gif "Minster - Minster - Read More"){kind=small}
Schizophrenia
Is a major psychiatric disease which affects millions. Management of progressive cognitive decline is recognised as a major unmet need.. ...
Is a major psychiatric disease which affects millions. Management of progressive cognitive decline is recognised as a major unmet need.. ...
Our Products
.gif "Minster - Minster - Home Page Thumb")
Tonabersat
Is from a new selective class of drugs called neuronal gap junction blockers, with real potential in the prevention of migraine...
Is from a new selective class of drugs called neuronal gap junction blockers, with real potential in the prevention of migraine...
.gif "Minster - Minster - Home Page Thumb"){kind=small}
Sabcomeline
Offering a new approach to the treatment of cognitive decline in schizophrenia...
Offering a new approach to the treatment of cognitive decline in schizophrenia...
News and features
5 March 2010
Compulsory Acquisition of Outstanding Minster Pharmaceuticals plc Shares
Compulsory Acquisition of Outstanding Minster Pharmaceuticals plc Shares
On 4 January 2010, the boards of Proximagen Neuroscience plc ("Proximagen") and Minster Pharmaceuticals plc ("Minster") announced the recommended offer by Proximagen for the entire issued and to be issued share capital of Minster (the "Offer").